Cell and tissue engineering and clinical applications: an overview.
Most human tissues do not regenerate spontaneously; this is why cell therapies and tissue engineering are promising alternatives. The principle is simple: cells are collected in a patient and introduced in the damaged tissue or in a tridimentional porous support and harvested in a bioreactor in which the physico-chemical and mechanical parameters are controlled. Once the tissues (or the cells) are mature they may be implanted. In parallel, the development of biotherapies with stem cells is a field of research in turmoil given the hopes for clinical applications that it brings up. Embryonic stem cells are potentially more interesting since they are totipotent, but they can only be obtained at the very early stages of the embryo. The potential of adult stem cells is limited but isolating them induces no ethical problem and it has been known for more than 40 years that bone marrow does possess the regenerating functions of blood cells. Finally, the properties of foetal stem cells (blood cells from the umbilical cord) are forerunners of the haematopoietic system but the ability of these cells to participate to the formation of other tissues is more problematic. Another field for therapeutic research is that of dendritic cells, antigen presenting cells. Their efficiency in cell therapy relies on the initiation of specific immune responses. They represent a promising tool in the development of a protective immune response against antigens which the host is usually unable to generate an efficient response (melanomas, breast against cancer, prostate cancer, ..). Finally, gene therapy, has been nourishing high hopes but few clinical applications can be envisaged in the short term, although potential applications are multiple (haemophilia, myopathies, ..). A large number of clinical areas stand as candidates for clinical applications: leukaemia and cancers, cardiac insufficiency and vascular diseases, cartilage and bone repair, ligaments and tendons, liver diseases, ophthalmology, diabetes, neurological diseases (Parkinson, Huntington disease, ..), .. Various aspects of this new regenerative therapeutic medicine are developed in this work.
Stoltz
J F
JF
UMR CNRS 7563, Groupe Ingénierie Cellulaire et Tissulaire, Université Henri Poincaré, Faculté de Médecine, 54500 Vandoeuvre les Nancy, France.
Bensoussan
D
D
Decot
V
V
Ciree
A
A
Netter
P
P
Gillet
P
P
D000818:Animals; D002356:Cartilage / Q000378:metabolism; D003585:Cell Biology; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D004622:Embryo, Mammalian / Q000166:cytology; D015316:Genetic Therapy; D006331:Heart Diseases / Q000628:therapy; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006801:Humans; D007107:Immune System; D019636:Neurodegenerative Diseases / Q000378:metabolism; D044968:Regenerative Medicine / Q000379:methods*; D013234:Stem Cells / Q000166:cytology; D023822:Tissue Engineering / Q000379:methods*